Review of preventative HIV vaccine clinical trials in South Africa
Open Access
- 14 August 2020
- journal article
- review article
- Published by Springer Nature in Archives of Virology
- Vol. 165 (11) , 2439-2452
Abstract
New HIV infections continue relentlessly in southern Africa, demonstrating the need for a vaccine to prevent HIV subtype C. In South Africa, the country with the highest number of new infections annually, HIV vaccine research has been ongoing since 2003 with collaborative public-private-philanthropic partnerships. So far, 21 clinical trials have been conducted in South Africa, investigating seven viral vectors, three DNA plasmids, four envelope proteins, five adjuvants and three monoclonal antibodies. Active vaccine candidates have spanned subtypes A, B, C, E and multi-subtype mosaic sequences. All were well tolerated. Four concepts were investigated for efficacy: rAd5-gag/pol/nef showed increased HIV acquisition in males, subtype C ALVAC/gp120/MF59 showed no preventative efficacy, and the trials for the VRC01 monoclonal antibody and Ad26.Mos4.HIV/subtype C gp140/ aluminum phosphate are ongoing. Future trials are planned with DNA/viral vector plus protein combinations in concert with pre-exposure prophylaxis, and sequential immunization studies with transmitted/founder HIV envelope to induce broadly neutralizing antibodies. Finally, passive immunization trials are underway to build on the experience with VRC01, including single and combination antibody trials with an antibody derived from a subtype-C-infected South African donor. Future consideration should be given to the evaluation of novel strategies, for example, inactivated-whole-virus vaccines.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (AI069453)
This publication has 56 references indexed in Scilit:
- Pre-existing immunity against vaccine vectors – friend or foe?Microbiology, 2013
- Phase I Safety and Immunogenicity Evaluations of an Alphavirus Replicon HIV-1 Subtype CgagVaccine in Healthy HIV-1-Uninfected AdultsClinical and Vaccine Immunology, 2012
- A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204)PLOS ONE, 2011
- Safety and efficacy of the HVTN 503/Phambili Study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b studyThe Lancet Infectious Diseases, 2011
- Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy AdultsAIDS Research and Human Retroviruses, 2011
- Characteristics of the Earliest Cross-Neutralizing Antibody Response to HIV-1PLOS Pathogens, 2011
- What will it take to achieve virtual elimination of mother-to-child transmission of HIV? An assessment of current progress and future needsSexually Transmitted Infections, 2010
- Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in ThailandNew England Journal of Medicine, 2009
- Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trialThe Lancet, 2008
- Neutralizing Antibody Responses in Acute Human Immunodeficiency Virus Type 1 Subtype C InfectionJournal of Virology, 2007